Cargando…
A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors
BACKGROUND: To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of irinotecan administered in combination with vincristine, temozolomide and bevacizumab in children with refractory solid tumors. METHODS: The study design included two dose levels (DL) of irinotecan given in...
Autores principales: | Venkatramani, Rajkumar, Malogolowkin, Marcio, Davidson, Tom B., May, William, Sposto, Richard, Mascarenhas, Leo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718768/ https://www.ncbi.nlm.nih.gov/pubmed/23894304 http://dx.doi.org/10.1371/journal.pone.0068416 |
Ejemplares similares
-
Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022) -
Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022) -
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation
por: Metts, Jonathan L., et al.
Publicado: (2022) -
DIPG-12. OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
por: Reel, Sarah, et al.
Publicado: (2023) -
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
por: Wang, Bi-Cheng, et al.
Publicado: (2022)